Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency Published, JLR Papers in Press, December 1, 2003. DOI 10.1194/jlr.M300198-JLR200
暂无分享,去创建一个
E. Schaefer | H. Mabuchi | Akihiro Inazu | K. Kajinami | B. Asztalos | M. Batista | Ernst J Schaefer | Katalin V. Horvath | Hiroshi Mabuchi | Akihiro Inazu | Bela F Asztalos | Katalin V Horvath | Kouji Kajinami | Chorthip Nartsupha | Caitlin E Cox | Marcelo Batista | Caitlin E. Cox | C. Cox | Chorthip Nartsupha
[1] E. Schaefer,et al. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients DOI 10.1194/jlr.M200037-JLR200 , 2002, Journal of Lipid Research.
[2] S. Yamashita,et al. Polydisperse low-density lipoproteins in hyperalphalipoproteinemic chronic alcohol drinkers in association with marked reduction of cholesteryl ester transfer protein activity. , 1992, Metabolism: clinical and experimental.
[3] M. Farnier,et al. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[4] B F Asztalos,et al. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. , 2001, Atherosclerosis.
[5] A. Tall,et al. Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. , 1991, Journal of lipid research.
[6] H. Mabuchi,et al. Rapid detection and prevalence of cholesteryl ester transfer protein deficiency caused by an intron 14 splicing defect in hyperalphalipoproteinemia , 1993, Human Genetics.
[7] S. Yamashita,et al. Frequency of intron 14 splicing defect of cholesteryl ester transfer protein gene in the Japanese general population--relation between the mutation and hyperalphalipoproteinemia. , 1993, Atherosclerosis.
[8] S. Yamashita,et al. Frequency of exon 15 missense mutation (442D:G) in cholesteryl ester transfer protein gene in hyperalphalipoproteinemic Japanese subjects. , 1995, Atherosclerosis.
[9] M. Lefevre,et al. Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[10] M. Jauhiainen,et al. The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein* , 2001, The Journal of Biological Chemistry.
[11] H. Suzuki,et al. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. , 1997, Journal of lipid research.
[12] D. Rader,et al. Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. , 1995, European journal of biochemistry.
[13] A. Zwinderman,et al. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.
[14] H. Brewer,et al. In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II. , 2002, Atherosclerosis.
[15] N. Fidge. High density lipoprotein receptors, binding proteins, and ligands. , 1999, Journal of lipid research.
[16] S. Yamashita,et al. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. , 1990, The Journal of clinical investigation.
[17] Gerard E. Dallal,et al. Change in &agr;1 HDL Concentration Predicts Progression in Coronary Artery Stenosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[18] L. Lagrost. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. , 1994, Biochimica et biophysica acta.
[19] S. Yamashita,et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. , 1994, Journal of biochemistry.
[20] H. Mabuchi,et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. , 1985, Atherosclerosis.
[21] E. Schaefer,et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. , 2002, Atherosclerosis.
[22] A. Reunanen,et al. Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men , 2000, European journal of clinical investigation.
[23] C. Sloop,et al. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. , 1993, Biochimica et biophysica acta.
[24] H. Mabuchi,et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.
[25] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[26] E. Schaefer,et al. Distribution of ApoA-I–Containing HDL Subpopulations in Patients With Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[27] S. Horiuchi,et al. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. , 1995, Journal of lipid research.
[28] A. Jonas,et al. Apolipoprotein A-II Modulates the Binding and Selective Lipid Uptake of Reconstituted High Density Lipoprotein by Scavenger Receptor BI* , 2001, The Journal of Biological Chemistry.
[29] S. Yamashita,et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[30] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[31] A. Tall,et al. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. , 1991, The Journal of clinical investigation.
[32] Ken-ichiHirano,et al. Genetic Cholesteryl Ester Transfer Protein Deficiency Is Extremely Frequent in the Omagari Area of Japan , 1997 .
[33] S. Yokoyama,et al. Rate of cholesteryl ester transfer between high and low density lipoproteins in human serum and a case with decreased transfer rate in association with hyperalphalipoproteinemia. , 1985, Journal of biochemistry.
[34] R. F. Johnston,et al. Autoradiography using storage phosphor technology , 1990, Electrophoresis.
[35] C. Fielding,et al. Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.
[36] W. A. Bradley,et al. Triglyceride, high density lipoprotein, and coronary heart disease. , 1993, Consensus statement. National Institutes of Health Consensus Development Conference.
[37] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[38] T. Arai,et al. Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[39] L. Havekes,et al. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[40] 康二 梶波,et al. Cholesteryl-Ester Transfer Activityの欠損を示す家族性高HDL血症の1家系 , 1987 .
[41] A. Tall. Plasma lipid transfer proteins. , 1986, Journal of lipid research.